Dr. Al-Dewik is currently a Director of Translational and Precision Medicine Research, Principal Investigator at Hamad Medical Corporation (HMC), and A/Professor in Human Genetics, Genomic and Precision Medicine Program, College of Health and Life Sciences, Hamad Bin Khalifa University (HBKU) in the State of Qatar. Dr. Al-Dewik was awarded his Ph.D. in Biomedical Sciences from Kingston University and St George’s Medical School, London, United Kingdom (UK) in Molecular Biology and Human Genetics. He received his postgraduate award in Cancer Biology & Therapeutics (CBT) program from Harvard Medical School (HMS), USA. He is licensed by the Ministry of Public Health in Qatar as a Clinical Scientist and by the Ministry of Health in Jordan as a Laboratory medicine specialist. Dr. Al-Dewik actively participates in several teaching modules at Qatar University (QU) and Hamad Bin Khalifa University (HBKU) and successfully supervises several Ph.D., MSc, and BSc students to their degrees. Dr. Al-Dewik is a member of several prestigious international professional bodies such as the Society for the Study of Inborn Errors of Metabolism (SSIEM), European Hematology Association (EHA), and the American Society of Hematology (ASH). Dr. Al-Dewik is successfully running several research grants funded by different funding bodies such as the Qatar National Research Fund QNRF, HMC. The team secured up to USD$ $9M between 2008 - 2023. Dr. Al-Dewik was awarded an innovation fund from Qatar Science and Technology Park (QSTP) to develop an absolute quantification molecular kit to measure a new biomarker and monitor Minimal Residual Disease (MRD). As a key principal investigator in the funded grants, he works with several international teams on translational molecular genetics. His research activities address high-priority inherited genetic disorders such as Homocystinuria, White Matter Diseases (WMDs), Leukemia, and Cancer ] as well as Clinical trials for Mucopolysaccharidosis type IV (MPS type IV) and Spinal Muscular Atrophy. Dr. Al-Dewik’s approach is multidisciplinary and collaborative in nature. His research interests include identifying the underlying genetic factors and signaling pathways involved in oncological diseases, novel biomarkers discovery, and studying the effects of founder mutations in the Qatari population for genetic disorders and leukemia. He contributes to the body of published knowledge in metabolic, genetics, and cancer with over 50 articles in peer-reviewed journals, book chapters, and abstracts